US Subsidiary Presence Modavar Pharmaceuticals LLC operates as the US subsidiary of Cadila Pharmaceutical Group, highlighting a strategic entry point for US-based sales opportunities and potential co-promotion or contract manufacturing collaborations within the US market.

Paroxetine ER Launch Recent product expansion with Paroxetine ER Tablets signals ongoing portfolio growth and appetite for US launches, presenting opportunities for related formulation development, manufacturing scale-up, or regional distribution partnerships.

Mid-sized Scale With 11-50 employees and revenue in the $10–$25 million range, Modavar sits in a mid-sized segment that can benefit from scalable manufacturing, fill-finish, and supply chain services tailored to growing specialty pharmaceutical products.

CGMP USFDA Focus Cadila’s CGMP-compliant, USFDA-approved facilities imply strong quality and regulatory capabilities; potential sales angles include contract manufacturing, quality systems outsourcing, and regulatory support services for buyers seeking compliant partners.

Global Quality Heritage As the US arm of a large global group with WHO, UK MHRA, TGA and other registrations, Modavar can leverage global quality and regulatory expertise to pursue multinational supply agreements and access to diverse markets.